SHANTANU BANDOPADHYAY

Dr. SHANTANU BANDOPADHYAY


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Critical Reviews™ in Therapeutic Drug Carrier Systems
Verified
Journal Article
Closed access
BSBhupinder Singh
Bhupinder Singh
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
RKRishi Kapil
Rishi Kapil
RSRamandeep Singh
Ramandeep Singh
OKOm Parkash Katare
Om Parkash Katare
Self-emulsifying drug delivery systems (SEDDS) possess unparalleled potential in improving oral bioavailability of poorly water-soluble drugs. Following their oral administration, these systems rapidly disperse in gastrointestinal fluids, yielding micro- or nanoemulsions containing the solubilized drug. Owing to its miniscule globule size, the micro/nanoemulsifed drug can easily be absorbed through lymphatic pathways, bypassing the hepatic first-pass effect. We present an exhaustive and updated account of numerous literature reports and patents on diverse types of self-emulsifying drug formulations, with emphasis on their formulation, characterization, and systematic optimization strategies. Recent advancements in various methodologies employed to characterize their globule size and shape, ability to encapsulate the drug, gastrointestinal and thermodynamic stability, rheological characteristics, and so forth, are discussed comprehensively to guide the formula-tor in preparing an effective and robust SEDDS formulation. Also, this exhaustive review offers an explicit discussion on vital applications of the SEDDS in bioavailability enhancement of various drugs, outlining an overview on myriad in vitro, in situ, and ex vivo techniques to assess the absorption and/ or permeation potential of drugs incorporated in the SEDDS in animal and cell line models, and the subsequent absorption pathways followed by them. In short, the current article furnishes an updated compilation of wide-ranging information on all the requisite vistas of the self-emulsifying formulations, thus paving the way for accelerated progress into the SEDDS application in pharmaceutical research.

1 December 2012 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
OKO.P. Katare
O.P. Katare
BSBhupinder Singh
Bhupinder Singh

1 January 2013 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
BSBhupinder Singh
Bhupinder Singh
RSRamandeep Singh
Ramandeep Singh
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
RKRishi Kapil
Rishi Kapil
BGBabita Garg
Babita Garg

4 August 2011 in Drug Delivery
Verified
Journal Article
Closed access
PDF file
BSBhupinder Singh
Bhupinder Singh
LKLalit Khurana
Lalit Khurana
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
RKRishi Kapil
Rishi Kapil
OKO.O.P. Katare
O.O.P. Katare
Carvedilol, a widely prescribed cardiovascular drug for hypertension and congestive heart failure, exhibits low and variable bioavailability owing to poor absorption and extensive hepatic first-pass metabolism. The current research work, therefore, entails formulation development of liquid self-nano-emulsifying drug delivery systems (SNEDDS) to enhance the bioavailability of carvedilol by facilitating its transport via lymphatic circulation. The formulation constituents, i.e. lipids, surfactants, and co-surfactants, were selected on the basis of solubility studies. Pseudo-ternary phase diagrams were constructed to embark upon the selection of blend of lipidic (i.e. Capmul PG8) and hydrophilic components (i.e. Cremophor EL as surfactant and Transcutol HP as co-surfactant) for efficient and robust formulation of SNEDDS. The SNEDDS, systematically optimized employing a central composite design (CCD), were evaluated for various response variables viz drug release parameters, emulsification time, emulsion droplet size, and mean dissolution time. In vitro drug release studies depicted that the release from SNEDDS systems followed a non-Fickian kinetic behavior. The TEM imaging of the optimized formulation affirmed the uniform shape and nano size of the system. Accelerated studies of the optimized formulation indicated high stability of the formulation for 6 months. The in situ perfusion studies carried out in wistar rats construed several fold augmentation in the permeability and absorption potential of the optimized formulation vis-à-vis marketed formulation. Thus, the present studies ratified the potential of SNEDDS in augmenting the oral bioavailability of BCS class II drugs.

8 November 2017 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SBSarwar Beg
Sarwar Beg
SSSUMANT SAINI
SUMANT SAINI
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
OKO. P. Katare
O. P. Katare
BSBhupinder Singh
Bhupinder Singh
This research work entails quality by design (QbD)-based systematic development of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil (OLM) with improved biopharmaceutical attributes. Quality target product profile (QTPP) was defined and critical quality attributes (CQAs) were earmarked. Solubility of drug was performed in various lipids for screening of them. NLCs were prepared by hot-microemulsion method using solid lipids, liquid lipids and surfactants with maximal solubility. Failure mode and effect analysis (FMEA) was carried out for identifying high risk formulation and process parameters. Further, principal component analysis (PCA) was applied on high risk parameters for evaluating the effect of type and concentration of lipids and surfactants on CQAs. Further, systematic optimization of critical material attributes (CMAs) was carried out using face centered cubic design and optimized formulation was identified in the design space. FMEA and PCA suggested suitability of stearic acid, oleic acid and Tween 80 as the CMAs for NLCs. Response surface optimization helped in identifying the optimized NLC formulation with particle size ∼250 nm, zeta potential 75%, in vitro drug release >80% within 6 h. Release kinetic modeling indicated drug release through Fickian-diffusion mechanism. Overall, these studies indicated successful development of NLCs using multivariate statistical approaches for improved product and process understanding.

6 January 2014 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
OKOp Katare
Op Katare
BSBhupinder Singh
Bhupinder Singh
To develop an optimized supersaturable self-nanoemulsifying drug delivery system (S-SNEDDS) in order to control drug precipitation along with surmounting poor aqueous solubility and P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2) efflux activity. Long-term stability of a previously reported formulation (OPT-LCT) consisting of Maisine 35-1 and Labrasol indicated rapid precipitation of ezetimibe. In vitro supersaturation test was carried out for selection of apt polymeric precipitation inhibitor (PPI). Following incorporation of the selected PPI, the precipitates from various formulations were differentiated employing optical microscopy, differential scanning calorimetry (DSC) and X-ray diffraction techniques. The S-SNEDDS was evaluated for globule size distribution. Also, lipid-lowering activity of S-SNEDDS was compared in relation to marketed product and optimized-long chain triglyceride. Subsequently, in situ perfusion studies were carried out for calculating various permeability and absorptivity parameters with specific focus on P-gp and MRP2 inhibition. Supersaturation test facilitated the selection of HPMC E5LV as the best PPI. The precipitates from the S-SNEDDS were identified as amorphous while crystalline ezetimibe precipitates were found when HPMC was absent in the formulation. Owing to heterogeneous distribution, globule size analysis was not practicable. Plasma lipid estimations showed that S-SNEDDS had considerable influence in increasing the high-density lipid levels. The single-pass intestinal perfusion parameters, namely fraction absorbed and effective permeability demonstrated significant improvement in rate and extent of absorption from S-SNEDDS. Co-administration of itraconazole and indomethacin as P-gp and MRP2 inhibitors, respectively revealed the potential of S-SNEDDS in reducing the efflux activities. The studies revealed that the systemic exposure of ezetimibe following oral administration can be substantially improved using S-SNEDDS.